Salvage of ischemic myocardium: a focus on JNK
- PMID: 17089887
- DOI: 10.1007/978-0-387-34817-9_14
Salvage of ischemic myocardium: a focus on JNK
Abstract
Myocardial infarction is a problem of utmost clinical significance, associated with an important morbidity and mortality. Actual treatment of this affection is focusing on the reperfusion of the occluded coronary-artery. A complementary approach would be to prevent the death of the ischemic myocardium by interacting with detrimental intracellular pathways. Several strategies have been successfully used to reduce the size of myocardial infarction in animal models. In this article, we will focus on the c-Jun N-terminal kinase (JNK), a member of the mitogen-activated (MAPK) protein kinase family and an important determinant of cell survival/death. We will review the role of JNK in cardiac ischemia/reperfusion and summarize recent advances in the use of JNK inhibitors to protect the myocardium.
Similar articles
-
Preventive effect of total flavones of Choerospondias axillaries on ischemia/reperfusion-induced myocardial infarction-related MAPK signaling pathway.Cardiovasc Toxicol. 2014 Jun;14(2):145-52. doi: 10.1007/s12012-013-9238-7. Cardiovasc Toxicol. 2014. PMID: 24297260
-
Insulin protects isolated hearts from ischemia/reperfusion injury: cross-talk between PI3-K/Akt and JNKs.Sheng Li Xue Bao. 2007 Oct 25;59(5):651-9. Sheng Li Xue Bao. 2007. PMID: 17940706
-
Remote vs. ischaemic preconditioning: the differential role of mitogen-activated protein kinase pathways.Cardiovasc Res. 2008 Apr 1;78(1):108-15. doi: 10.1093/cvr/cvm114. Epub 2007 Dec 20. Cardiovasc Res. 2008. PMID: 18096574
-
Protein kinase activation and myocardial ischemia/reperfusion injury.Cardiovasc Res. 2004 Feb 15;61(3):427-36. doi: 10.1016/j.cardiores.2003.09.031. Cardiovasc Res. 2004. PMID: 14962474 Review.
-
Myocardial ischemia and reperfusion injury.Cardiovasc Pathol. 2005 Jul-Aug;14(4):170-5. doi: 10.1016/j.carpath.2005.03.006. Cardiovasc Pathol. 2005. PMID: 16009313 Review.
Cited by
-
c-Jun N-Terminal Kinases (JNKs) in Myocardial and Cerebral Ischemia/Reperfusion Injury.Front Pharmacol. 2018 Jul 5;9:715. doi: 10.3389/fphar.2018.00715. eCollection 2018. Front Pharmacol. 2018. PMID: 30026697 Free PMC article. Review.
-
c-Jun N-terminal kinase (JNK-1) confers protection against brief but not extended ischemia during acute myocardial infarction.J Biol Chem. 2011 Apr 22;286(16):13995-4006. doi: 10.1074/jbc.M110.211334. Epub 2011 Feb 15. J Biol Chem. 2011. PMID: 21324895 Free PMC article.
-
Cardioprotective Effects of a Selective c-Jun N-terminal Kinase Inhibitor in a Rat Model of Myocardial Infarction.Biomedicines. 2023 Feb 27;11(3):714. doi: 10.3390/biomedicines11030714. Biomedicines. 2023. PMID: 36979693 Free PMC article.
-
p21-activated kinase improves cardiac contractility during ischemia-reperfusion concomitant with changes in troponin-T and myosin light chain 2 phosphorylation.Am J Physiol Heart Circ Physiol. 2012 Jan 1;302(1):H224-30. doi: 10.1152/ajpheart.00612.2011. Epub 2011 Oct 28. Am J Physiol Heart Circ Physiol. 2012. PMID: 22037191 Free PMC article.
-
Alarmins and c-Jun N-Terminal Kinase (JNK) Signaling in Neuroinflammation.Cells. 2020 Oct 24;9(11):2350. doi: 10.3390/cells9112350. Cells. 2020. PMID: 33114371 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous